Interim report Q1 2021

January – March · Revenues amounted to MSEK 713.0 (793.6), corresponding to a decrease of -10% for the period. ·  Revenues amounted to MSEK 713.0 ( 793.6), corresponding to a decrease of -10% for the period. · The organic growth* during the first quarter was -16%. The currency impact in the quarter was -1% while the acquisitions of the product portfolios Proct® from Leo Pharma and Pevaryl® from Johnson & Johnson generated growth of +7%. · EBIT (Operating Profit) amounted to MSEK 128.1 (104.1), corresponding to growth of 23%. · EBITDA* amounted to MSEK 259.8 (209.3)